90results about How to "Meet medication needs" patented technology

The invention discloses a mussel mucoprotein gel for repairing and reliving itching. The mussel mucoprotein gel is prepared from the following components in percentage by weight: 0.15%-0.2% of mussel mucoprotein, 0.5%-2% of a macromolecule host material, 3%-10% of a humectant, 1%-5% of a surfactant, 0.1%-0.5% of a preservative, 1%-2% of a protein protectant, 0.5%-3% of a stabilizer, 0.5%-1% of a bacteriostatic agent, 0.8%-5.2% of a pH modifier and the balance of purified water. The mussel mucoprotein gel has good biological adhesion, is rapidly and effectively adhered to a wound surface, is capable of rapidly reliving itching and easing pain, and has the advantages of being low in immunogenicity, good in biocompatibility with a human body, convenient to use, free of thrill to skin, safe, nontoxic and free of bad reaction.

The present invention relates to a new preparation of a Chinese medicine. The present invention particularly relates to a novel preparation of a drug with the effervescent tablet property and the dispersing agent property. In the effervescent dispersing tablet of the present invention, the weight ratio of each components are as following, which comprises 5 percentage to 60 percentage of effervescent agent, 3 percentage to 30 percentage of effervescing agent, 3 percentage to 30 percentage of disintegrant, 3 percentage to 30 percentage of excipient of the hydrophilic medicine, 1 percentage to 5 percentage of correctant. The effervescent dispersing tablet of the present invention is a novel preparation of the Chinese medicine, which has the effervescent tablet property and the dispersing agent property. The present medicine is a tablet, which can produce the gas in the water, which can disaggregate quickly and disperse evenly. The present invention is a novel preparation of the medicine, which can generate the gas; as a result the medicine can disaggregate more quickly. The drug loading dosage of the agent is large, which is beneficial for improving the dispersion uniformity, the dissolution and the bioavailability of the medicine. The present invention has the characteristics of convenience for oral administration and small dose. The present invention can sufficiently display the drug efficacy in order to meet the drug requirement of the patients.

The invention discloses tenofovir disoproxil fumarate dispersible tablets and a preparation method thereof. The tenofovir disoproxil fumarate dispersible tablets are prepared from tenofovir disoproxil fumarate as an effective pharmaceutical ingredient and pharmaceutically acceptable auxiliary ingredients, wherein the pharmaceutically acceptable auxiliary ingredients comprise a filler, a disintegrant, a lubricant, a surfactant and a flavoring agent. The tenofovir disoproxil fumarate dispersible tablets prepared by the invention have appropriate hardness, small weight difference, bright and clean tablet surfaces and good taste, fully meet the requirements on the disintegration time and dispersion uniformity of dispersible tablets, and notably improve the pharmaceutical bioavailability, and in addition, the tenofovir disoproxil fumarate dispersible tablets have quick dissolution rate, the dissolution percentage of the product is about 80-90% in 2 minutes, and the product is almost completely dissolved in 5 minutes.

The invention provides a recombinant expression vector for expressing LL-37 polypeptide, recombinant lactococcus lactis, an antiviral drug, a construction method and application, and belongs to the technical field of gene engineering. A skeleton plasmid for constructing the recombinant expression vector is PNZ8149; a fusion gene is inserted into the recombinant expression vector; the nucleotide sequence of the fusion gene is shown as SEQ ID NO: 1. The recombinant expression vector disclosed by the invention can be efficiently expressed in lactococcus lactis, and the LL-37 obtained by expression can effectively inhibit SARS coronavirus and SARS-CoV2 coronavirus. The invention also provides recombinant lactococcus lactis containing the recombinant expression vector in the scheme. According to the recombinant lactococcus lactis disclosed by the invention, an antiviral polypeptide drug LL-37 can be input into a human body in an oral form, the antiviral effect is good, and the production cost is low.

The invention provides a nifedipine sustained release tablet and a preparation method thereof. The nifedipine sustained release tablet is prepared from nifedipine, sodium alginate, lactose, a PVP-K30 ethanol solution, magnesium stearate and calcium gluconate. The preparation method comprises the following steps: preparing raw materials, preparing the PVP-K30 ethanol solution, thoroughly mixing the raw materials according to the prescribed amount, then adding an appropriate amount of PVP-K30 ethanol solution, and performing mixed granulation; after drying, adding a right amount of magnesium stearate, mixing totally, and then performing tabletting and packaging. The nifedipine sustained release tablet provided by the invention has the advantages of good safety, dissolution curve and stability, low cost and the like.

The present invention is Notoginseng Vulnerary extract and its preparation process and application. All the ingredients of Notoginseng Vulnerary except borneol are extracted to obtain the effective components, and the extracted effective components together with borneol are prepared into different dosage forms for both orally taking and external applying. The present invention expands the application range of Notoginseng Vulnerary.

The invention discloses a planting method for tetrastigma hemsleyanum Diels et Gilg. The planting method mainly comprises the following steps of seedling selection, seedling culture, field management, pest and disease control, timely harvesting and the like. Rattan seedlings need to be treated through rooting hormone before seedling culture and insertion implantation, so the survival rate of the rattan seedlings can reach 90% or more. By the adoption of the method, the tetrastigma hemsleyanum Diels et Gilg can be produced on a large scale, so rich tetrastigma hemsleyanum Diels et Gilg herbs can be provided for people, and the medicine consumption requirements of people are satisfied. Besides, the planting method has good economic and social benefits.

The invention relates to the technical field of medicine production, in particular to a preparation method of an artificial bear gall powder preparation. The preparation method comprises the followingsteps of S1, preparing raw materials: poultry and livestock gall powder, beta cyclodextrin, cane sugar, dextrin, steviosin, menthol, peppermint oil, magnesium stearate, talcum powder, ethanol, starch, licorice root extractum powder, stevioside, PVA-4000, PVA-6000, glycerine, polyvinylpyrrolidone, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, polyethylene glycol, dibutyl phthalate, a coloring agent and silicon dioxide; S2, dissolving the poultry and livestock gall powder with a buffered solution, performing centrifugation under the condition of 11000g, performing repeated filtrationto obtain filter residues and filtrate, and performing freeze drying and preservation on the filter residues; and S3, loading the filtrate in a reactor loaded with 7[alpha]-hydroxysteroid dehydrogenase. According to the preparation method disclosed by the invention, the artificial bear gall powder is designed to be a raw material medicine, and the artificial bear gall powder preparation is developed, so that the problem that natural bear gall raw materials are valuable and scarce is solved, and besides, a new medicine preparation is provided for human.

The invention relates to the pharmacy field of blood products, in particular to a method for preparing FEIBA (factor eight inhibitor bypassing activity) from a human plasma Cohn component III serving as a raw material. The method for preparing FEIBA from the human plasma Cohn component III serving as the raw material comprises steps as follows: (1), dissolution of the component III; (2), addition of a precipitator and centrifugalization; (3), inactivation of viruses; (4), gel adsorption; (5), washing and elution of gel; (6), condensation and solution replacement; (7) generation of FEIBA.

The invention provides an artemether liposome for injection. The artemether liposome is prepared by adopting an ethanol injection method. The method is simple in preparation process and can be appliedto industrial production. According to the invention, by selecting appropriate material components and adopting appropriate preparation processes, the prepared artemether liposome is small in particle size (150-200nm) and uniform in particle size distribution and has the encapsulation efficiency greater than 90%. The artemether liposome is slowly released in vivo to avoid adverse reactions causedby excessively high concentration of drugs at the initial stage of the injection. Furthermore, the inventor finds that the artemether liposome prepared with the method has high stability, high bioavailability, good resolubility and long storage time, and meets needs of drug use.

The invention discloses a Naoxueshu preparation method which comprises the following steps: (1) fetching acorus gramineus and cortex moutan, and extracting volatile oil; (2,3,4) fetching radix astragali, achyranthes bidentata, ligusticum wallichii and rheum officinale, grinding and merging with the residue; sequentially adding water with pH value of (1.5-2.5), (6.5-7.0) and (7.8-8.5); and heating and extracting; (5) fetching leech, adding normal saline and soaking; (6,7,8) sequentially adding water with pH value of (1.5-2.5), (6.5-7.0) and (7.8-8.5) into the filter residue, and heating and extracting; (9) merging the filtrate obtained in the steps (5,6,7,8), concentrating and drying to obtain hirudin; and (10) merging the filtrate obtained in the steps (2,3,4), and concentrating to obtain clear paste; adding the volatile oil and hirudin, and mixing uniformly; and adding pharmaceutically acceptable carrier or accessories to obtain a medicinal preparation. The Naoxueshu preparation obtained by the method has the advantages of high content of active ingredients, high bioavailability, better adaptability to human body absorption and the like.

The invention provides a metoprolol pulse osmotic pump controlled release tablet and a preparation method thereof. The controlled release tablet comprises a tablet core, a time lag coating layer and a controlled release coating layer with a release orifice from inside to outside, wherein the tablet core consists of a drug containing layer and a boosting layer, based on the gross weight of the drug containing layer, the drug containing layer comprises 5-65 wt% of metoprolol as active material and 35-95 wt% of pharmaceutically acceptable carrier; based on the gross weight of the boosting layer, the boosting layer comprises 30-85 wt% of swelling agent and 15-70 wt% of osmotic pressure promoting agent; the weight gain of the time lag coating layer is 5-50 wt% of the tablet core; and the weight gain of the controlled release coating layer is 3-30 wt% of the tablet core. The metoprolol pulse osmotic pump controlled release tablet has three-stage release behavior, and is characterized in that the tablet has 2-5 hours time lag at the initial period after being taken orally, increased release is showed at the intermediate period, and release at constant speed is showed at the later period.

The invention relates to a silky fowl soft capsule and a preparation method thereof. The silky fowl soft capsule is prepared by: subjecting, by weight, 50-60 parts of a silky fowl extract, 100-110 parts of deerhorn glue, 50-60 parts of vinegar processed turtle shell, 30-50 parts of calcined oyster, 50-60 parts of Mantis Egg-case, 100-110 parts of ginseng, 20-30 parts of astragalus, 120-130 parts of Chinese angelica, 100-110 parts of Radix Paeoniae Alba, 100-110 parts of vinegar processed cyperus rotundus, 50-60 parts of radix asparagi, 20-30 parts of licorice, 200-220 parts of rehmannia glutinosa, 200-220 parts of Radix Rehmanniae Preparata, 50-60 parts of Ligusticum wallichii, 20-30 parts of Radix Stellariae, 100-110 parts of Salvia Miltiorrhiza, 100-110 parts of Chinese yam, 50-60 parts of fried Euryale ferox, and 30-50 parts of Cornu Cervi Degelatinatum to extraction and adding appropriate auxiliary materials.

A nakedflower beautyberry injection is prepared from naked flower beautyberry through pulverizing, sieving, decocting 1-3 times, collecting decoction, filtering, concentrating, laying aside, concentrating again, and preparing injection, powder injection, perfusion, or eyedrops.

The present invention discloses a kind of Chinese medicine injection for treating cardiac and cerebral vascular diseases and its preparation process, and the injection and freeze dried powder for injection has dioscin as main component. The present invention also discloses nanometer dioscin preparation prepared through nanometer technology. The present invention has the advantages of fast acting, high bioavailability, fast absorption, etc.

The invention provides a medicine composition for preventing and treating respiratory system diseases. The medicine composition is an externally applied preparation prepared from the following raw materials and auxiliaries in parts by weight: 10-50 parts of semen brassicae, 10-50 parts of rhizoma corydalis, 5-40 parts of kansui roots, 5-40 parts of asarum, 50-300 parts of a disintegrating agent, 30-60 parts of adhesive and 2-15 parts of a lubricating agent. The invention further provides a preparation method and application of the medicine composition. The medicine composition is prepared from specific raw materials and auxiliaries in a specific dosage. Compared with a traditional acupoint application preparations, the medicine composition has the advantages of equivalent curative effect and convenience in use, can be used for remarkably reducing the drug irritation for skin and improving the acceptance of drug users, and can meet the medication requirement of patients. The medicine composition is simple in preparation process, low in cost and high in production efficiency, is available for volume production, and can meet the market requirement.